Who is sponsoring NCT02672865?

NCT02672865 is sponsored by Loma Linda University.

What drugs are being tested in NCT02672865?

Interventions in NCT02672865: Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

What condition does NCT02672865 study?

NCT02672865 studies Locally Advanced Malignant Neoplasm, Gastric Cancer.

Is NCT02672865 still recruiting?

NCT02672865 is currently completed. Last updated 12 April 2019.

Last reviewed 2019-04-12 · How we verify

NCT02672865

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer

Completed Phase 1 Last updated 12 April 2019

What this trial tests

Phase 1 trial testing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Malignant Neoplasm in 4 participants. Completed in 3 October 2018.

Timeline

2 February 2016

Primary endpoint
3 October 2018

3 October 2018

Quick facts

Lead sponsor	Loma Linda University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	2 February 2016
Primary completion	3 October 2018
Estimated completion	3 October 2018
Sites	1 location across United States

Drugs / interventions tested

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — full drug profile →

Conditions studied

Locally Advanced Malignant Neoplasm — all drugs for Locally Advanced Malignant Neoplasm →
Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Loma Linda University

Who can join

Adults 18 to 75, any sex, with Locally Advanced Malignant Neoplasm or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine safety and feasibility of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in patients with locally advanced gastric cancer undergoing standard surgical resection. Patients will be treated with HIPEC using a single dose of mitomycin 15mg/m2 and cisplatin 50mg/m2 at 41-42 C for 90 minutes, during the definitive surgical resection for gastric cancer. HIPEC will be performed after resection but before anastomosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Photodynamic Therapy and Hyperthermia in Combination Treatment-Neglected Forces in the Fight against Cancer.
Bienia A, Wiecheć-Cudak O, Murzyn AA, Krzykawska-Serda M. · · 2021 · cited 36× · PMID 34452108 · DOI 10.3390/pharmaceutics13081147

Verify or expand the search:

Other trials of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Trials testing the same drug.

NCT07493421 — To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating P · NA · recruiting
NCT07353177 — Effects of HIPEC on Postoperative Bowel Motility and Complications · active not recruiting
NCT03348150 — Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. · Phase 3 · active not recruiting

Other recruiting trials for Locally Advanced Malignant Neoplasm

Currently open trials in the same condition.

NCT05099809 — Registry Trial to Evaluate the Safety and Efficacy of Hyperthermia in Locally Advanced Cancers · recruiting
NCT03743649 — Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Under · Phase 2, PHASE3 · active not recruiting
NCT04053517 — Financial Distress in Advanced Cancer Patients · active not recruiting
NCT03671226 — Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their · NA · active not recruiting
NCT03021486 — Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Canc · Phase 2, PHASE3 · active not recruiting

Other Loma Linda University trials

Trials by the same sponsor.

NCT07213843 — Combined Circulatory and Dietary Interventions for Neuropathy · NA · not yet recruiting
NCT07130812 — Blood Flow Restriction Training as a Targeted Intervention for Rowers With Back Pain. · NA · recruiting
NCT06673342 — Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake · NA · completed
NCT06445842 — Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women · NA · recruiting
NCT07396831 — Necessity of Post-operative Eye Drops · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02672865 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Loma Linda University
Last refreshed: 12 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02672865.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing